Project Number: 6040-32000-072-024-T
Project Type: Trust Fund Cooperative Agreement
Start Date: Mar 1, 2019
End Date: Dec 31, 2021
Virulent Newcastle disease virus is a world wide concern for the poultry industry, and causes severe clinical disease with high mortality in susceptible populations. Although the United States is typically free of the disease, we are currently experiencing a prolonged outbreak. Vaccines are commonly used for the control of clinical disease, but traditional vaccination approaches have not been shown to completely prevent clinical disease. In recent years, new viral vectored vaccines that can be administered in the hatchery have been licensed for use in the United States, and have become widely used in the poultry industry. However, little data is publically available on how protective this next generation of vaccine will be when administered by itself or in combination with commonly used live Newcastle disease virus vaccines.
The ARS Southeast Poultry Research Laboratory, Athens, Georgia, in collaboration with Merck Animal Health will conduct a vaccination trial using a recently licensed Herpesvirus of turkeys vectored vaccine that expresses the fusion protein of Newcastle disease virus. This next generation vaccine, that will be given at day of age, will be used by itself and in combination with a live Newcastle disease vaccine virus. Challenge with the highly virulent California 2018 Newcastle disease virus will be conducted, and viral sheding after challenge and clinical disease will be the primary measures of protection.